Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial (Q43121565)

14 November 2017

title

Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial (English)

1 reference

14 November 2017

1 reference

2

1 reference

14 November 2017

5

1 reference

14 November 2017

D Macis

4

0 references

Gunnar Mellgren

11

object named as

G Mellgren

1 reference

14 November 2017

Aliana Guerrieri Gonzaga

0 references

author name string

D Serrano

1

1 reference

14 November 2017

C-F Zambon

3

1 reference

14 November 2017

H Johansson

6

1 reference

14 November 2017

A Guerrieri-Gonzaga

7

1 reference

14 November 2017

M Plebani

8

1 reference

14 November 2017

D Basso

9

1 reference

14 November 2017

J Gjerde

10

1 reference

14 November 2017

N Rotmensz

12

1 reference

14 November 2017

A Decensi

13

1 reference

14 November 2017

B Bonanni

14

1 reference

14 November 2017

publication date

23 March 2010

1 reference

The Pharmacogenomics Journal

14 November 2017

published in

1 reference

14 November 2017

volume

11

1 reference

14 November 2017

issue

2

1 reference

14 November 2017

page(s)

100-107

1 reference

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

14 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Drug metabolism and variability among patients in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

The CYP2C19 enzyme polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Cytochrome P450 pharmacogenetics and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

CYP2C19*17 is associated with decreased breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Polymorphism in the CYP2D6 Tamoxifen-Metabolizing Gene Influences Clinical Effect but Not Hot Flashes: Data From the Italian Tamoxifen Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Optimizing endocrine therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.17

21 January 2018

Identifiers

DOI

10.1038/TPJ.2010.17

1 reference

14 November 2017

1 reference